BR112012022879A2 - composto, composição farmacêutica, uso do composto e método de tratamento - Google Patents
composto, composição farmacêutica, uso do composto e método de tratamentoInfo
- Publication number
- BR112012022879A2 BR112012022879A2 BR112012022879A BR112012022879A BR112012022879A2 BR 112012022879 A2 BR112012022879 A2 BR 112012022879A2 BR 112012022879 A BR112012022879 A BR 112012022879A BR 112012022879 A BR112012022879 A BR 112012022879A BR 112012022879 A2 BR112012022879 A2 BR 112012022879A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- treatment method
- compound use
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1004178.8A GB201004178D0 (en) | 2010-03-12 | 2010-03-12 | Enzyme inhibitors |
| PCT/GB2011/050477 WO2011110858A1 (en) | 2010-03-12 | 2011-03-10 | Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012022879A2 true BR112012022879A2 (pt) | 2016-06-14 |
Family
ID=42261512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012022879A BR112012022879A2 (pt) | 2010-03-12 | 2011-03-10 | composto, composição farmacêutica, uso do composto e método de tratamento |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9156844B2 (pt) |
| EP (1) | EP2545056B1 (pt) |
| JP (1) | JP6065180B2 (pt) |
| KR (1) | KR20130018671A (pt) |
| CN (1) | CN102858774B (pt) |
| AU (1) | AU2011225902B2 (pt) |
| BR (1) | BR112012022879A2 (pt) |
| CA (1) | CA2792725C (pt) |
| GB (1) | GB201004178D0 (pt) |
| HK (1) | HK1180322A1 (pt) |
| IL (1) | IL221873A (pt) |
| MX (1) | MX2012010004A (pt) |
| RU (1) | RU2581839C2 (pt) |
| SG (1) | SG184012A1 (pt) |
| UA (1) | UA109000C2 (pt) |
| WO (1) | WO2011110858A1 (pt) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI568735B (zh) * | 2011-09-14 | 2017-02-01 | 吉斯藥品公司 | 新穎化合物 |
| UA118021C2 (uk) * | 2012-12-18 | 2018-11-12 | К'Єзі Фармачеутічі С.П.А. | Гетероциклічні сполуки, фармацевтична композиція, яка містить їх, і їх застосування в лікуванні захворювання або стану, в якому бере участь hne |
| US20140221335A1 (en) | 2013-02-06 | 2014-08-07 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| US9115093B2 (en) | 2013-03-04 | 2015-08-25 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| KR20160097227A (ko) | 2013-12-16 | 2016-08-17 | 키에시 파르마슈티시 엣스. 피. 에이. | 인간 호중구 엘라스타제 억제제로서 테트라하이드로트리아졸로피리미딘 유도체 |
| USRE47493E1 (en) | 2014-02-20 | 2019-07-09 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| US9487528B2 (en) | 2014-06-09 | 2016-11-08 | Chiesi Farmaceutici S.P.A. | Compounds |
| RU2016148395A (ru) | 2014-06-12 | 2018-07-12 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Новые соединения |
| US9657015B2 (en) | 2014-07-31 | 2017-05-23 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| US9475779B2 (en) | 2014-07-31 | 2016-10-25 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| US9458113B2 (en) | 2014-07-31 | 2016-10-04 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| US9290457B2 (en) | 2014-07-31 | 2016-03-22 | Boehringer Ingelheim International Gmbh | Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| US9440930B2 (en) | 2014-07-31 | 2016-09-13 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| US9890169B2 (en) | 2015-12-14 | 2018-02-13 | Chiesi Farmaceutici S.P.A. | Triazolinone compounds as HNE inhibitors |
| AU2017272405C1 (en) | 2016-05-31 | 2021-01-14 | Chiesi Farmaceutici S.P.A. | Imidazolone compounds as human Neutrophil Elastase inhibitors |
| EP3464269B1 (en) | 2016-05-31 | 2020-04-01 | Chiesi Farmaceutici S.p.A. | Heterocyclic compounds for use in the treatment of a hne related disease |
| EP3464268B1 (en) | 2016-05-31 | 2020-03-11 | Chiesi Farmaceutici S.p.A. | Novel compounds |
| CN114650819A (zh) | 2019-09-17 | 2022-06-21 | 美莱奥生物制药第四有限公司 | 用于治疗移植物排斥、闭塞性细支气管炎综合征和移植物抗宿主病的阿维来司他 |
| PT4106757T (pt) | 2020-04-16 | 2023-11-17 | Mereo Biopharma 5 Inc | Métodos que envolvem o inibidor da elastase neutrofílica alvelestat para o tratamento de doenças respiratórias mediadas pela deficiência de alfa 1 antitripsina |
| TW202325294A (zh) | 2021-10-20 | 2023-07-01 | 英商梅瑞奧生物製藥４有限公司 | 用於治療纖維化之嗜中性球彈性蛋白酶抑制劑 |
| AR128054A1 (es) | 2021-12-22 | 2024-03-20 | Chiesi Farm Spa | Sal derivada de triazolona como inhibidor de elastasa de neutrófilos |
| AR128053A1 (es) | 2021-12-22 | 2024-03-20 | Chiesi Farm Spa | Sal derivada de triazolona como inhibidor de elastasa de neutrófilos |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| AU2003255492A1 (en) * | 2002-09-10 | 2004-04-30 | Bayer Healthcare Ag | Heterocyclic derivatives |
| GB0502258D0 (en) * | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
| GB0520743D0 (en) * | 2005-10-12 | 2005-11-23 | Argenta Discovery Ltd | Compounds and their use |
| WO2009013444A1 (en) | 2007-07-25 | 2009-01-29 | Argenta Discovery Limited | Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors |
| EP2024367B1 (en) * | 2006-05-04 | 2010-09-08 | Pulmagen Therapeutics (Inflammation) Limited | Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors |
| GB0608844D0 (en) * | 2006-05-04 | 2006-06-14 | Argenta Discovery Ltd | Enzyme inhibitors |
| DE102006031314A1 (de) * | 2006-07-01 | 2008-01-03 | Bayer Healthcare Aktiengesellschaft | Verwendung von 1,4-Diaryl-dihydropyrimidin-2-on-Derivaten zur Behandlung der pulmonalen arteriellen Hyptertonie |
| US20100010024A1 (en) * | 2006-07-01 | 2010-01-14 | Bayer Healthcare Ag | Use of1,4-diaryl-dihydropyrimidine-2-on derivatives for treating pulmonary arterial hypertension |
| DE102008022521A1 (de) * | 2008-05-07 | 2009-11-12 | Bayer Schering Pharma Aktiengesellschaft | 1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung |
| BRPI0821027B8 (pt) * | 2007-12-20 | 2021-05-25 | Bayer Ip Gmbh | 4-(4-ciano-2-tioaril)di-hidropirimidinonas para tratamento e/ou prevenção de lesões do pulmão e do sistema cardiovascular, seu processo de preparação e seu uso, e medicamento |
| DE102009004197A1 (de) * | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclisch anellierte Diaryldihydropyrimidin-Derivate und ihre Verwendung |
| GB201004179D0 (en) * | 2010-03-12 | 2010-04-28 | Pulmagen Therapeutics Inflamma | Enzyme inhibitors |
-
2010
- 2010-03-12 GB GBGB1004178.8A patent/GB201004178D0/en not_active Ceased
-
2011
- 2011-03-10 US US13/640,001 patent/US9156844B2/en active Active
- 2011-03-10 KR KR1020127022792A patent/KR20130018671A/ko active IP Right Grant
- 2011-03-10 EP EP11709794.9A patent/EP2545056B1/en active Active
- 2011-03-10 CA CA2792725A patent/CA2792725C/en not_active Expired - Fee Related
- 2011-03-10 AU AU2011225902A patent/AU2011225902B2/en not_active Ceased
- 2011-03-10 BR BR112012022879A patent/BR112012022879A2/pt not_active IP Right Cessation
- 2011-03-10 CN CN201180011540.4A patent/CN102858774B/zh not_active Expired - Fee Related
- 2011-03-10 WO PCT/GB2011/050477 patent/WO2011110858A1/en active Application Filing
- 2011-03-10 RU RU2012138579/04A patent/RU2581839C2/ru not_active IP Right Cessation
- 2011-03-10 JP JP2012556587A patent/JP6065180B2/ja not_active Expired - Fee Related
- 2011-03-10 SG SG2012067328A patent/SG184012A1/en unknown
- 2011-03-10 MX MX2012010004A patent/MX2012010004A/es active IP Right Grant
- 2011-10-03 UA UAA201210667A patent/UA109000C2/uk unknown
-
2012
- 2012-09-10 IL IL221873A patent/IL221873A/en not_active IP Right Cessation
-
2013
- 2013-06-28 HK HK13107621.7A patent/HK1180322A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN102858774A (zh) | 2013-01-02 |
| HK1180322A1 (en) | 2013-10-18 |
| MX2012010004A (es) | 2012-10-05 |
| KR20130018671A (ko) | 2013-02-25 |
| UA109000C2 (uk) | 2015-07-10 |
| EP2545056B1 (en) | 2017-09-06 |
| CN102858774B (zh) | 2015-05-06 |
| AU2011225902A1 (en) | 2012-10-04 |
| IL221873A (en) | 2016-05-31 |
| JP2013522182A (ja) | 2013-06-13 |
| WO2011110858A1 (en) | 2011-09-15 |
| RU2012138579A (ru) | 2014-04-20 |
| RU2581839C2 (ru) | 2016-04-20 |
| CA2792725C (en) | 2018-01-02 |
| JP6065180B2 (ja) | 2017-01-25 |
| AU2011225902B2 (en) | 2015-11-05 |
| CA2792725A1 (en) | 2011-09-15 |
| SG184012A1 (en) | 2012-10-30 |
| US20130150380A1 (en) | 2013-06-13 |
| US9156844B2 (en) | 2015-10-13 |
| GB201004178D0 (en) | 2010-04-28 |
| EP2545056A1 (en) | 2013-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012022879A2 (pt) | composto, composição farmacêutica, uso do composto e método de tratamento | |
| BR112012022878A2 (pt) | composto, composição farmacêutica, uso do compostos e método de tratamento | |
| BR112012031226A2 (pt) | composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica | |
| BR112015002541A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente. | |
| BR112013010725A2 (pt) | método, e, composição | |
| BR112013016772A2 (pt) | composto, uso do composto, composição farmacêutica, oligonucleotídeo e conjugado | |
| BR112013008259A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR112014002621A2 (pt) | anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento | |
| BR112013009935A2 (pt) | compostos, composição, método e semente tratada | |
| IL225597A0 (en) | Pharmaceutical preparation, methods of treatment and its uses | |
| BR112013009708A2 (pt) | aparelhos, métodos e composições para tratamento endodôntico | |
| BR112013015397A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR112013011448A2 (pt) | composto, composição farnmacêutica, e, uso do composto | |
| BR112013006016A2 (pt) | compostos de azabenzotiazol, composições e métodos de uso | |
| BR112012031232A2 (pt) | método, dispositivo e uso | |
| BR112012004335A2 (pt) | composto, composição farmacêutica, e, uso do composto. | |
| ITTO20110641A1 (it) | Composizioni farmaceutiche e metodi di trattamento | |
| BR112012000831A2 (pt) | compostos, composições farmacêuticas e métodos relacionados | |
| BRPI1006996A2 (pt) | composição, método e uso | |
| BRPI0720323A2 (pt) | composto, método de tratamento, composição farmacêutica e uso do composto | |
| BR112014003556A2 (pt) | método de tratamento de vírus, e, composição farmacêutica | |
| EP2924042A4 (en) | BIS-BETA-CARBOLINE COMPOUND AND METHOD OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| BR112012031967A2 (pt) | composto, uso de um composto, combinação de um composto e composição farmacêutica | |
| BR112013012175A2 (pt) | combinação, coadministração, uso e método | |
| BR112013006482A2 (pt) | composição oral e método de formação e uso da mesma. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
| B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
| B07E | Notice of approval relating to section 229 industrial property law |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2506 DE 15/01/2019. |